| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
1.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.48 - $21.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
| Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
11 |
| Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
| Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
| Total People Sold |
5 |
5 |
5 |
5 |
| Total Sell Transactions |
9 |
11 |
11 |
12 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bb Biotech Ag |
10% Owner |
– – • |
2021-09-17 |
4 |
B |
$19.93 |
$3,986,680 |
D/D |
200,000 |
6,875,564 |
2.45 |
-42% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-09-16 |
4 |
B |
$20.94 |
$8,376,800 |
D/D |
400,000 |
6,675,564 |
2.45 |
-46% |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2021-06-24 |
4 |
OE |
$16.00 |
$436,337 |
D/D |
26,076 |
108,550 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$21.74 |
$1,630,170 |
D/D |
75,000 |
6,275,564 |
2.45 |
-12% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-06-16 |
4 |
B |
$21.04 |
$2,104,390 |
D/D |
100,000 |
6,200,564 |
2.45 |
-8% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-06-15 |
4 |
B |
$20.53 |
$1,539,615 |
D/D |
75,000 |
6,100,564 |
2.45 |
-5% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-06-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,025,564 |
|
-10% |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2021-05-14 |
4 |
D |
$29.49 |
$71,248 |
D/D |
(2,416) |
82,474 |
|
- |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
84,890 |
|
- |
|
| Spitznagel Thomas |
Sr VP, BPD & Manufacturing |
• – – |
2021-04-15 |
4 |
AS |
$30.91 |
$154,550 |
D/D |
(5,000) |
0 |
|
-29% |
|
| Spitznagel Thomas |
Sr VP, BPD & Manufacturing |
• – – |
2021-04-15 |
4 |
OE |
$7.51 |
$37,550 |
D/D |
5,000 |
5,000 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2021-03-22 |
4 |
AS |
$33.00 |
$495,000 |
D/D |
(15,000) |
143,460 |
|
-24% |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2021-03-22 |
4 |
AS |
$32.00 |
$125,344 |
D/D |
(3,917) |
79,890 |
|
-24% |
|
| Peters Jeffrey Stuart |
General Counsel |
• – – |
2021-03-08 |
4 |
AS |
$26.50 |
$576,349 |
D/D |
(21,749) |
0 |
|
-6% |
|
| Peters Jeffrey Stuart |
General Counsel |
• – – |
2021-03-08 |
4 |
OE |
$11.50 |
$250,114 |
D/D |
21,749 |
21,749 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2021-01-28 |
4 |
OE |
$0.94 |
$8,490 |
D/D |
6,000 |
158,460 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-12-29 |
4 |
AS |
$24.10 |
$12,050 |
D/D |
(500) |
44,468 |
|
33% |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-12-29 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-11-30 |
4 |
AS |
$23.35 |
$11,675 |
D/D |
(500) |
44,468 |
|
30% |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-11-30 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-10-28 |
4 |
AS |
$20.69 |
$31,035 |
D/D |
(1,500) |
44,468 |
|
35% |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-10-28 |
4 |
OE |
$1.51 |
$2,265 |
D/D |
1,500 |
45,968 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-09-28 |
4 |
AS |
$25.33 |
$12,665 |
D/D |
(500) |
44,468 |
|
-12% |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2020-09-28 |
4 |
OE |
$1.51 |
$755 |
D/D |
500 |
44,968 |
|
- |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2020-09-18 |
4 |
AS |
$32.00 |
$586,848 |
D/D |
(18,339) |
83,807 |
|
-33% |
|
57 Records found
|
|
Page 1 of 3 |
|
|
0.82 (5.32%) 
